Dendreon and its fall from grace over the past few months has no...

Dendreon and its fall from grace over the past few months has no real bearing on PRR and it's SP

Remember Dendreon got FDA approval for Provenge over a year ago and it is being clinicaly used throught the US for prostate care

It has met with some costing problems etc and that is the reason for its share value falling some 70 odd percent from a high around US$50

PRR of course is still a long way from FDA approval,2 years plus,if it happens, and I am confident that it will, that is why I am invested

PRR has no revenues coming in at present but hopefully that is set to change when the Dubai Hospital starts administering Cvac, around the New year it seems

If all goes well in Dubai and the World Health Council start to recognise that Cvac is giving prolonged life spans to the women of the Middle East suffering from Ovarian cancer, then there is a bright outlook for Prima Biomed

DYOR

Keep the faith